
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

October 31, 2003

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

Florida
(State or other jurisdiction
of incorporation)

333-100568
(Commission
File Number)

59-3410522
(IRS Employer
Identification No.)

**12085 Research Drive
Alachua, Florida 32615**
(Address of principal executive offices including zip code)

(386) 418-4018
Registrant's telephone number, including area code

None
(Former name or former address, if changed since last report.)

ITEM 7. FINANCIAL INFORMATION AND EXHIBITS

Exhibit No.	Description
99.1	Press Release

ITEM 9. REGULATION FD DISCLOSURE

Oragenics, Inc. announces today that it has granted stock options to Paul Hassie and Brian Anderson.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 31st day of October, 2003.

ORAGENICS, INC.

(Registrant)

BY: /s/ Mento A. Soponis

Mento A. Soponis

President, Principal Executive Officer and a member of the
Board of Directors.

ORAGENICS, INC.

12085 Research Drive
Alachua, Florida
Tel: 386.418.4018 Fax: 386-462-0875
www.oragenics.com

NEWS RELEASE

Trading Symbol - ORA.U (TSX-V)

October 31, 2003

Grant of Stock Options

Alachua, Florida - Oragenics, Inc. (the "Company") announces that it has granted stock options to Paul Hassie, Chief Financial Officer of the Company, and Brian Anderson, a director of the Company. On July 31, 2003, Mr. Hassie was granted options to purchase 20,000 shares at US\$2.65 per share, exercisable until July 31, 2008. On September 3, 2003, Mr. Anderson was granted options exercisable at a price of US\$4.00 per share exercisable until September 3, 2008. The options will vest over a period of 3 years. Any shares acquired on the exercise of the options will be subject to a hold period of four months from the date the options were granted and the options will terminate 90 days after the optionee ceases to serve the Company. The grant of the options is subject to TSX Venture Exchange acceptance.

On Behalf of the Board of Directors of

ORAGENICS, INC.

/s/ Mento A. Sponis
Mento A. Soponis, President

Contact: Mento A. ("Chuck") Soponis, Chief Executive Officer
Oragenics, Inc., Tel: 386-418-4018

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this News Release.
